desvenlafaxine SR — Competitive Intelligence Brief

desvenlafaxine SR (desvenlafaxine SR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Depression, Anxiety.

phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter, Norepinephrine transporter Depression, Anxiety Small molecule

Target snapshot

desvenlafaxine SR (desvenlafaxine SR) — Wyeth is now a wholly owned subsidiary of Pfizer. Desvenlafaxine SR is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
desvenlafaxine SR TARGET	desvenlafaxine SR	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter, Norepinephrine transporter
Venlafaxine and Lamotrigine	Venlafaxine and Lamotrigine	University Health Network, Toronto	marketed	SNRI + anticonvulsant combination	Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
SSRI/Venlafaxine	SSRI/Venlafaxine	AstraZeneca	phase 3	SSRI/Venlafaxine	Serotonin transporter, Norepinephrine transporter
lidocaine+adjunct tramadol	lidocaine+adjunct tramadol	Bagcilar Training and Research Hospital	phase 3	Local anesthetic, weak opioid agonist	Voltage-gated sodium channels, mu-opioid receptor, serotonin transporter, norepinephrine transporter
SSRI/Clomipramine	SSRI/Clomipramine	AstraZeneca	phase 3	SSRI/SNRI	Serotonin transporter, Norepinephrine transporter
desvenlafaxine succinate sustained release tablets	desvenlafaxine succinate sustained release tablets	Pfizer	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter, Norepinephrine transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class